Skip to content

HOME
About
Our Focus
AD109
OSA Stories + Community
Careers
News

News

Apnimed to Present at the Jefferies Virtual Healthcare Conference

May 25, 2021

Year

2025 2024 2023 2022 2021 2020

Positive Phase 3 Data for AD109 from Second Pivotal Trial

Read More

Apnimed Unveils Topline Data from Second Phase 3 Trial of AD109, Validating Efficacy and Impact for OSA.

Read More

It’s our goal to elevate treatment for people with OSA—subscribe for updates.

Contact Us

Name:(Required)

Email:(Required)

I am a:(Required)

Comments

This field is for validation purposes and should be left unchanged.

NYSE: [SYMBOL]
$xxx.xx
+1.20 (0.5%)
Last updated: 7/03/2024 12:11 PM

Contact Us
Privacy Policy
Terms and Conditions
Cookie Settings

Follow Us

NYSE: [SYMBOL]
$xxx.xx
+1.20 (0.5%)
Last updated: 7/03/2024 12:11 PM

©2024 Apnimed, Inc. All rights reserved. Apnimed is a Cambridge, MA-based clinical stage company dedicated to the discovery of novel therapies for sleep apnea and related disorders. The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.